tegoprazan + bismuth potassium citrate + amoxicillin + clarithromycin

This is a **quadruple combination therapy** comprising **tegoprazan** (a potassium-competitive acid blocker), **bismuth potassium citrate** (a bismuth salt), **amoxicillin** (a beta-lactam antibiotic), and **clarithromycin** (a macrolide antibiotic), used primarily for the eradication of *Helicobacter pylori* infection. **Tegoprazan** potently blocks gastric acid secretion by competitively inhibiting the potassium-binding site of gastric H^+/K^+-ATPase, improving the gastric pH to facilitate antibiotic efficacy[1][3]. **Bismuth potassium citrate** exerts antimicrobial activity against *H. pylori* and provides mucosal protective effects. **Amoxicillin** and **clarithromycin** directly inhibit bacterial growth through their respective mechanisms: amoxicillin targets bacterial cell wall biosynthesis, and clarithromycin inhibits bacterial protein synthesis by binding the 50S ribosomal subunit[3][1]. This quadruple regimen is used as a first-line or salvage therapy for *H. pylori* eradication, especially in regions with high antibiotic resistance, and has been shown to have high efficacy and acceptable safety in clinical studies[1][3][5].

Brand names

K-CAB

Other names

tegoprazan quadruple therapyTBAC quadruple therapytegoprazan-based bismuth quadruple therapy